Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the first quarter of 2013.
“We expect the last patients to complete our two pivotal Phase 3 clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer by the end of this month, which should allow us to release topline data from the studies in the third quarter of this year,” said Mitchell S. Steiner, MD, CEO of GTx.
Help employers find you! Check out all the jobs and post your resume.
